Table 1. Comparison between BNP2 and Rituximab effects.
CD20 | BNP2 | RITUXIMAB | |
(MFI) | (% killing) | (% killing) | |
BJAB | 316,8 | 92,0 | 18,9 |
BJAB-High | 602,9 | 93,2 | 20,6 |
BJAB-low | 103,1 | 83,1 | 0,6 |
Pz1 | 73,6 | 77,4 | 0,0 |
Pz2 | 22,2 | 81,7 | 8,9 |
Pz3 | 25,3 | 55,1 | 9,9 |
Pz4 | 41,4 | 44,9 | 18,0 |
Pz5 | 64,5 | 47,9 | 21,8 |
Median | 41,4 | 55,1 | 9,9 |
BJAB cells were sorted to obtain High-CD20 and Low-CD20 cells. Mononuclear cells were purified from untreated CLL patients. Cells were analyzed for CD20 expression (MFI-mean fluorescence intensity) and then incubated with BNP2 for 48 hours to induce apoptosis. Cells were also incubated with Rituximab + NHS as a source of Complement for 1 h to induce CDC. Residual viable cells were measure using MTT assay.